OM - NASDAQ
Outset Medical, Inc.
$4.60
-6.3%Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
At a Glance
Live SnapshotOutset Medical, Inc. Management Team
Mr. Nabeel Ahmed
Chief Financial Officer
Compensation
$743,384
Dr. Michael Aragon M.D.
Chief Medical Officer
Mr. John L. Brottem J.D.
General Counsel & Secretary
Compensation
$672,677
Mr. James S. Mazzola
Head of Investor Relations
Ms. Leslie L. Trigg
President, Chief Executive Officer & Chairman
Compensation
$1,602,397
Ms. Jennifer Sipple
Senior Vice President of Customer Experience
Mr. Marc Nash
Senior Vice President of Operations and R&D
Dinamarie Stefani
Senior Vice President of Regulatory Affairs & Quality Assurance
Ms. Laura Romike
Senior Vice President of Sales
Amelia Merrill
Vice President of People Operations & Culture
Outset Medical, Inc. Insider Positioning
During the last 12 months, insiders have sold $255K worth of OM shares, with no buying activity reported.
3 Months
0
0.00
7.7K
28.36K
-28K
-$28K
3-6 Months
0
0.00
40.9K
193.03K
-193K
-$193K
6-9 Months
0
0.00
3.1K
13.90K
-14K
-$14K
9-12 Months
0
0.00
1.5K
19.70K
-20K
-$20K
Top Buyers
No buying activity
Top Sellers
Trigg Leslie
Director, Officer: Chair And Ceo
$119K
Brottem John L.
Officer: General Counsel
$81K
Nash Marc
Officer: Evp Operations R&D & Service
$49K
Drexler Karen
Director
$7K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $255K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
OM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 11, 2025 | June 02, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | February 04, 2025 | March 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 11, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 13, 2023 | April 13, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 14, 2022 | May 31, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 21, 2021 | June 03, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.